French recommendations have been proposed for psychotropics use and possible adaptations during the SARS-CoV-2 epidemic. Between uncertainties linked to the lack of data and speculations about possible benefits of psychotropics against the coronavirus, we propose here elements allowing to base the pharmacotherapeutic decisions potentially useful in Covid+ patients with psychiatric disorders.
Enjeux de l'utilisation des psychotropes dans le cadre de la pandémie au SARS-Cov-2./ [Challenges for psychotropics in the context of the SARS-Cov-2 pandemic]